CD8A and neoplasm: Besides, Jeanbart et al. demonstrated potent CD8 + -based immune responses, a significant tumor regression, and an enhanced survival in an E.G7-OVA animal model, targeting tumor-draining lymph nodes by poly(propylene sulfide)-based nanoparticles that contain the model antigen OVA and the CpG adjuvant in their surface.